HOME     CONTACT     BACK

 
 
 
THE PHARMA REVIEW (OCTOBER - NOVEMBER 2007)

Gastroretentive Drug Delivery System

Dr. H. P. Tipnis

Abstract: More and more people all over the world are cutting their medicine costs by switching to generic drugs. Dispensing of generic drugs at the counters of pharmacies across America is as high as 61% under the Medicare Prescription Drug Plan (PDP). Generic drugs are 50 to 70% less expensive than the branded drugs. In 2005, cholesterol lowering drug Zocor ( Simvastatin ) and Pravachol ( pravastatin) and antidepresant Zoloft (sertraline ) and Welbatrin ( bupropion ) and nasal spray fluticasone, together cost $ 9.4 billion, but after the expiry of patents, the same drugs cost was $6.6 billion in 2006. Generic competition, after the expiry of patents for Pozac ( fluoxetine ), Zantacc (ranitidine) Taxol (paclitaxel) and Platinol ( cisplatin ), is estimated to have saved the customers more than $9 billion. In 2008 several brands like Prevacid ( lansoprazole ), Imitex ( samatriptan ), zyrtec ( cetirizine ) and Effexor ( Venlafaxine ) are expected to lose their patents and will go generic. Nearly $62billion worth of branded drugs will go off the patent between 2007 to 2012; $16 billion of branded drugs went off the patent in 2006.

Go to Content Index Page

PHARMA REVIEW - ARTICLES ARCHIVE ( COMPLETE LIST)

The above content is an abstract only. For the full Article please contact:
KONGPOSH Publications Pvt. Ltd.
ICS House, C-19, Commercial Complex, SDA, Opp. IIT Gate, New Delhi, India -110016
Tel.: 26855839, 20057149, Fax: 91-11-26855876
Email: info@kppub.com / fpc@vsnl.com, Website: http://www.kppub.com

 
 
 

 Copyright 2008. KONGPOSH PUBLICATIONS Pvt. Ltd.